BioStock Investor Meeting: Interview with Cyxone
Cyxone’s interim CEO Carl-Magnus Högerkorp was interviewed by BioStock after his presentation at the BioStock Investor Meeting. In the interview, Högerkorp tells us more about the upcoming phase II study with the company’s leading candidate Rabeximod, and answers the question of where the company expects to be in a year.
See the interview with Cyxone’s interim CEO Carl-Magnus Högerkorp below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
